IP Library Granted Patent US 10,010,722
Granted Patent B2
US 10,010,722 · App. 13/790,774 · Granted Jul 3, 2018

Transducer cartridge for an ultrasound therapy head

View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 10,010,722
App. No.
13/790,774
Granted
Jul 3, 2018
Kind
B2
Abstract

Medical ultrasound systems. A base unit is included having system electronics, a user interface and ultrasound control electronics. An ultrasound therapy head is in electronic communication with the base unit. The therapy head includes a replaceable, sealed transducer cartridge with a coupling fluid therein. A cooling system is provided for cooling the coupling fluid. A plurality of guide indicators are positioned around the therapy head to align with crossed lines on a patient so as to properly align the therapy head prior to use. The therapy head can provide variable treatments to an area while the therapy head is in contact with a patient.

Claims (27)

1. A cartridge connectable to a body to form a therapy head, the body including a driver, said cartridge comprising:

an acoustic coupling liquid;

a sealed enclosure comprising a wall, an interior filled with the acoustic coupling liquid, and an exterior surface, the wall including an acoustic window and an opening sealed to prevent loss of the acoustic coupling liquid from the interior;

a high intensity ultrasound transducer in the acoustic coupling liquid inside the sealed enclosure, the high intensity ultrasound transducer having an output surface generally aligned with the acoustic window;

a bearing member passing through the opening in the wall and coupled to the high intensity ultrasonic transducer, said bearing member being attachable to the driver in the body to move the high intensity ultrasonic transducer within the sealed enclosure and thereby orient a direction of acoustic energy delivered from the output surface through the acoustic window by the high intensity ultrasonic transducer; and

a heat exchanger including a first plurality of tubes that is located inside the sealed enclosure, the first plurality of tubes thermally coupled with the acoustic coupling liquid to remove heat generated by the high intensity ultrasound transducer from the acoustic coupling liquid without removing the acoustic coupling liquid from the sealed enclosure, and the first plurality of tubes configured to receive a cooling liquid for circulation through the first plurality of tubes to cool the acoustic coupling liquid while the acoustic coupling liquid remains isolated from the cooling liquid;

wherein the wall includes the acoustic window, a top plate, and sidewalls extending from the top plate to the acoustic window sides, the high intensity ultrasound transducer is configured to move inside the sealed enclosure over a range of movement, and the first plurality of tubes are arranged about a perimeter of the sidewalls to be outside of the range of movement of the high intensity ultrasound transducer.

2. The cartridge of claim 1 wherein the transducer is a short stack transducer assembly.

3. The cartridge of claim 1 wherein the acoustic coupling liquid comprises water.

4. The cartridge of claim 1 further comprising:

a metallization layer coating the wall of the sealed enclosure and the acoustic window, the metallization layer configured to reduce a gas permeability of the wall and the acoustic window.

5. The cartridge of claim 4 wherein the metallization layer has a thickness of 500 Ångstroms to 1500 Ångstroms.

6. The cartridge of claim 5 wherein the metallization layer has a thickness that is less than X, where X=[((α−0.09)*1000)/0.03]+500, with X being the metallization layer thickness in Ångstroms, and α being a maximum acceptable acoustic attention in dB in a transmission window.

7. The cartridge of claim 1 wherein the acoustic coupling liquid is not circulated through the wall of the enclosed space during the operation of the high intensity ultrasound transducer.

8. The cartridge of claim 1 wherein the acoustic coupling liquid is not circulated through the opening in the wall of an enclosed space during operation of the high intensity ultrasound transducer.

9. The cartridge of claim 1 wherein the acoustic coupling liquid comprises a volume of 100 to 200 milliliters.

10. The cartridge of claim 1 wherein the sealed enclosure is self-contained.

11. The cartridge of claim 1 wherein the acoustic coupling liquid surrounds the high intensity ultrasound transducer and is configured to couple the acoustic energy from the high intensity ultrasound transducer for delivery through the acoustic window.

12. The cartridge of claim 1 wherein the cartridge is removably connected to the body and is disposable upon removal from the body.

13. The cartridge of claim 1 wherein the cartridge is removable from the body and replaceable as a single unit.

14. The cartridge of claim 1 wherein the acoustic coupling liquid is not removed from the sealed enclosure for degassing during operation of the high intensity ultrasound transducer.

15. The cartridge of claim 1 wherein the acoustic coupling liquid includes dissolved oxygen at a level of less than 12 parts per million.

16. The cartridge of claim 1 wherein the sealed enclosure includes a wall comprised of a first plastic, and the acoustic window is comprised of a second plastic different from the first plastic.

17. The cartridge of claim 16 further comprising:

a metallization layer coating the wall of the sealed enclosure and the acoustic window, the metallization layer configured to reduce a gas permeability of the wall and the acoustic window.

18. The cartridge of claim 1 wherein the first plurality of tubes extend in a first serpentine path around the perimeter of the sealed enclosure.

19. The cartridge of claim 18 wherein the heat exchanger further includes a second plurality of tubes, the second plurality of tubes are arranged about the perimeter of the sidewalls to be outside of the range of movement of high intensity ultrasound transducer, and the second plurality of tubes extend in a second serpentine path around the perimeter of the sealed enclosure.

Assignments (15)
RELEASE OF SECURITY INTEREST Recorded Nov 20, 2025
From: THE BANK OF NEW YORK MELLON, AS NOTES COLLATERAL AGENT
To: BAUSCH HEALTH AMERICAS, INC.; BAUSCH & LOMB INCORPORATED; BAUSCH HEALTH US, LLC; SOLTA MEDICAL, INC.; MEDICIS PHARMACEUTICAL CORPORATION; SALIX PHARMACEUTICALS, INC.; SALIX PHARMACEUTICALS, LTD.; SANTARUS, INC.; ORAPHARMA, INC.; PRECISION DERMATOLOGY, INC.
Reel/Frame 073637/0126 →
RELEASE OF SECURITY INTEREST Recorded Nov 20, 2025
From: THE BANK OF NEW YORK MELLON, AS NOTES COLLATERAL AGENT
To: BAUSCH & LOMB INCORPORATED; BAUSCH HEALTH US, LLC; SOLTA MEDICAL, INC.; MEDICIS PHARMACEUTICAL CORPORATION; SALIX PHARMACEUTICALS, INC.; SALIX PHARMACEUTICALS, LTD.; SANTARUS, INC.; ORAPHARMA, INC.; PRECISION DERMATOLOGY, INC.; BAUSCH HEALTH AMERICAS, INC.
Reel/Frame 073654/0242 →
RELEASE OF SECURITY INTEREST Recorded Nov 20, 2025
From: THE BANK OF NEW YORK MELLON, AS NOTES COLLATERAL AGENT
To: BAUSCH HEALTH COMPANIES INC.; BAUSCH HEALTH, CANADA INC.; BAUSCH HEALTH IRELAND LIMITED; SOLTA MEDICAL IRELAND LIMITED
Reel/Frame 073654/0300 →
U.S. PATENT SECURITY AGREEMENT Recorded Jun 13, 2025
From: MEDICIS PHARMACEUTICAL CORPORATION; ORAPHARMA, INC.; BAUSCH HEALTH US, LLC (F/K/A VALEANT PHARMACEUTICALS NORTH AMERICA LLC); PRECISION DERMATOLOGY, INC.; SALIX PHARMACEUTICALS, INC.; SANTARUS, INC.; BAUSCH HEALTH AMERICAS, INC.; SOLTA MEDICAL, INC.
To: THE BANK OF NEW YORK MELLON
Reel/Frame 071564/0463 →
U.S. PATENT SECURITY AGREEMENT Recorded Jun 13, 2025
From: MEDICIS PHARMACEUTICAL CORPORATION; ORAPHARMA, INC.; BAUSCH HEALTH US, LLC (F/K/A VALEANT PHARMACEUTICALS NORTH AMERICA LLC); PRECISION DERMATOLOGY, INC.; SALIX PHARMACEUTICALS, INC.; SANTARUS, INC.; BAUSCH HEALTH AMERICAS, INC.; SOLTA MEDICAL, INC.
To: JPMORGAN CHASE BANK, N.A.
Reel/Frame 071566/0200 →
RELEASE OF SECURITY INTEREST Recorded Apr 8, 2025
From: BARCLAYS BANK PLC, AS COLLATERAL AGENT
To: SOLTA MEDICAL, INC.; PRECISION DERMATOLOGY, INC.; BAUSCH HEALTH IRELAND LIMITED (F/K/A/ VALEANT PHARMACEUTICALS IRELAND LIMITED); SALIX PHARMACEUTICALS, INC.; SALIX PHARMACEUTICALS, LTD; SANTARUS, INC.; MEDICIS PHARMACEUTICAL CORPORATION; HUMAX PHARMACEUTICAL S.A.; SOLTA MEDICAL IRELAND LIMITED; BAUSCH & LOMB MEXICO, S.A. DE C.V.; BAUSCH+LOMB OPS B.V.; BAUSCH HEALTH AMERICAS, INC.; BAUSCH HEALTH COMPANIES INC.; BAUSCH HEALTH HOLDCO LIMITED; BAUSCH HEALTH MAGYARORSZAG KFT (A/K/A BAUSCH HEALTH HUNGARY LLC); BAUSCH HEALTH POLAND SPOLKA Z OGRANICZONA ODPOWIEDZIALNOSCIA (F/K/A VALEANT PHARMA POLAND SPOLKA Z OGRANICZONA ODPOWIEDZIALNOSCIA); BAUSCH HEALTH US, LLC; BAUSCH HEALTH, CANADA INC. / SANTE BAUSCH, CANADA INC.; ICN POLFA RZESZOW SPOLKA AKCYJNA (A/K/A ICN POLFA RZESZOW S.A.); ORAPHARMA, INC.; PRZEDSIEBIORSTWO FARMACEUTYCZNE JELFA SPOLKA AKCYJNA (A/K/A PRZEDSIEBIORSTWO FARMACEUTYCZNE JELFA S.A.); SOLTA MEDICAL DUTCH HOLDINGS B.V.; V-BAC HOLDING CORP.; VRX HOLDCO LLC; 1261229 B.C. LTD.; 1530065 B.C. LTD.
Reel/Frame 070778/0199 →
SECURITY AGREEMENT (SECOND LIEN) Recorded Oct 5, 2022
From: BAUSCH HEALTH US, LLC; BAUSCH HEALTH AMERICAS, INC.; MEDICIS PHARMACEUTICAL CORPORATION; ORAPHARMA, INC.; PRECISION DERMATOLOGY, INC.; SALIX PHARMACEUTICALS, INC.; SALIX PHARMACEUTICALS, LTD.; SANTARUS, INC.; SOLTA MEDICAL, INC.
To: THE BANK OF NEW YORK MELLON, AS NOTES COLLATERAL AGENT
Reel/Frame 061606/0468 →
SECURITY AGREEMENT (FIRST LIEN) Recorded Oct 4, 2022
From: BAUSCH HEALTH US, LLC; BAUSCH HEALTH AMERICAS, INC.; MEDICIS PHARMACEUTICAL CORPORATION; ORAPHARMA, INC.; PRECISION DERMATOLOGY, INC.; SALIX PHARMACEUTICALS, INC.; SALIX PHARMACEUTICALS, LTD.; SANTARUS, INC.; SOLTA MEDICAL, INC.
To: THE BANK OF NEW YORK MELLON, AS NOTES COLLATERAL AGENT
Reel/Frame 061595/0066 →
SECURITY INTEREST Recorded Jun 13, 2022
From: BAUSCH HEALTH COMPANIES INC.; BAUSCH HEALTH, CANADA INC.; BAUSCH HEALTH IRELAND LIMITED; SOLTA MEDICAL IRELAND LIMITED
To: THE BANK OF NEW YORK MELLON
Reel/Frame 060346/0705 →
SECURITY AGREEMENT Recorded Feb 10, 2022
From: BAUSCH & LOMB INCORPORATED; BAUSCH HEALTH US, LLC; SOLTA MEDICAL, INC.; MEDICIS PHARMACEUTICAL CORPORATION; SALIX PHARMACEUTICALS, INC.; SALIX PHARMACEUTICALS, LTD.; SANTARUS, INC.; ORAPHARMA, INC.; PRECISION DERMATOLOGY, INC.; BAUSCH HEALTH AMERICAS, INC.
To: THE BANK OF NEW YORK MELLON
Reel/Frame 059121/0001 →
SECURITY INTEREST Recorded Jun 8, 2021
From: BAUSCH & LOMB INCORPORATED; BAUSCH HEALTH US, LLC; SOLTA MEDICAL, INC.; MEDICIS PHARMACEUTICAL CORPORATION; SALIX PHARMACEUTICALS, INC.; SALIX PHARMACEUTICALS, LTD.; SANTARUS, INC.; ORAPHARMA, INC.; PRECISION DERMATOLOGY, INC.; BAUSCH HEALTH AMERICAS, INC.
To: THE BANK OF NEW YORK MELLON, AS NOTES COLLATERAL AGENT
Reel/Frame 056811/0814 →
SECURITY INTEREST Recorded Jan 21, 2021
From: BAUSCH HEALTH IRELAND LIMITED; SALIX PHARMACEUTICALS, INC.; BAUSCH & LOMB INCORPORATED; SOLTA MEDICAL, INC.
To: THE BANK OF NEW YORK MELLON, AS NOTES COLLATERAL AGENT
Reel/Frame 054984/0345 →
SECURITY INTEREST Recorded Jan 21, 2021
From: BAUSCH HEALTH IRELAND LIMITED; SALIX PHARMACEUTICALS, INC.; BAUSCH & LOMB INCORPORATED; SOLTA MEDICAL, INC.
To: BARCLAYS BANK PLC, AS COLLATERAL AGENT
Reel/Frame 054984/0324 →
MERGER AND CHANGE OF NAME Recorded Jul 2, 2020
From: LIPOSONIX, INC.; SOLTA MEDICAL, INC.
To: SOLTA MEDICAL, INC.
Reel/Frame 053105/0887 →
SECURITY INTEREST Recorded Mar 11, 2019
From: BAUSCH HEALTH AMERICAS, INC.; BAUSCH & LOMB INCORPORATED; BAUSCH HEALTH US, LLC; SOLTA MEDICAL, INC.; MEDICIS PHARMACEUTICAL CORPORATION; SALIX PHARMACEUTICALS, INC.; SALIX PHARMACEUTICALS, LTD.; SANTARUS, INC.; ORAPHARMA, INC.; PRECISION DERMATOLOGY, INC.
To: THE BANK OF NEW YORK MELLON, AS NOTES COLLATERAL AGENT
Reel/Frame 048556/0758 →